NAP1L5 and Alzheimer disease: Consistent with our predictions that NAP1L5 was downregulated in the brain tissues of AD patients (Figure 1I), NAP1L5 mRNA levels further verified to be reduced in N2a-APP695sw (Figure 1J), a previously verified cell model of AD (Li et al., 2015; Zhang et al., 2017a,b; Sun et al., 2020; Yao et al., 2022).